Clazosentan

Drug Profile

Clazosentan

Alternative Names: ACT-108475; AXV 034; AXV 034343; Pivlaz

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Chugai Pharmaceutical; Roche
  • Developer Actelion Pharmaceuticals
  • Class Anti-ischaemics; Dioxanes; Neuroprotectants; Pyridines; Pyrimidines; Small molecules; Sulfonamides; Tetrazoles
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cerebral vasospasm
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cerebral vasospasm

Most Recent Events

  • 05 Sep 2016 Actelion plans two phase III trials for Cerebral vasospasm (in patients with aneurysmal subarachnoid haemorrhage) in Japan (IV) (JapicCTI163368; JapicCTI163369)
  • 01 May 2016 Phase-III clinical trials in Cerebral vasospasm in Japan (IV) (JapicCTI163368; JapicCTI163369)
  • 29 Sep 2015 Actelion plans the phase II REVERSE trial for Cerebral vasospasm in Switzerland (IV) (NCT02560532)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top